osteoporosis	is a	metabolic bone disease
osteoporosis	characterized by	reduced bone mass
osteoporosis	characterized by	porous bones
osteoporosis	increases risk of	fragility fracture
osteoporosis	leads to	vertebral fracture
osteoporosis	leads to	hip fracture
osteoporosis	diagnosed by	DEXA scan
osteoporosis	diagnosed by	bone mineral density test
DEXA scan	measures	bone mineral density
bone mineral density	assessed by	T-score
osteoporosis	treated with	bisphosphonates
osteoporosis	treated with	denosumab
osteoporosis	treated with	teriparatide
osteoporosis	treated with	raloxifene
osteoporosis	treated with	calcium supplementation
osteoporosis	treated with	vitamin D supplementation
bisphosphonates	decrease	bone turnover
bisphosphonates	associated with	osteonecrosis of the jaw
bisphosphonates	associated with	atypical femoral fracture
denosumab	reduces	vertebral fracture risk
denosumab	inhibits	RANKL
teriparatide	increases	bone formation
raloxifene	reduces	vertebral fracture risk
calcium supplementation	supports	bone density
calcium supplementation	recommended for	osteoporosis management
vitamin D supplementation	recommended for	osteoporosis management
glucocorticoid therapy	increases risk of	osteoporosis
corticosteroid use	increases risk of	osteoporosis
menopause	increases risk of	osteoporosis
age	increases risk of	osteoporosis
women	have higher risk of	osteoporosis
smoking	increases	osteoporosis risk
alcohol use	increases	osteoporosis risk
sedentary lifestyle	increases	osteoporosis risk
weight-bearing exercise	improves	bone density
weight-bearing exercise	reduces	fracture risk
physical activity	reduces	falls risk
DEXA screening	recommended for	postmenopausal women
bone density loss	predicts	fracture risk
osteoporosis	associated with	increased mortality after fracture
osteoporosis	increases risk for	vertebral compression fracture
osteoporosis	increases risk for	hip fracture
older adults	include	postmenopausal women
postmenopausal women	at higher risk for	osteoporosis
bone turnover marker	used for	monitoring osteoporosis therapy
CTX	is a	bone resorption marker
P1NP	is a	bone formation marker
osteoporosis management	includes	calcium supplementation
osteoporosis management	includes	vitamin D supplementation
osteoporosis management	includes	exercise therapy
calcium	essential for	bone health
vitamin D	essential for	calcium absorption
parathyroid hormone	regulates	calcium homeostasis
bone density testing	monitors	osteoporosis progression
vertebral fracture	indicates	osteoporosis severity
osteoporosis	affects	quality of life
osteoporosis	influences	fall risk
calcium intake	correlates with	bone density
physical therapy	reduces	fall risk
bisphosphonate therapy	requires	renal function monitoring
renal function	influences	bisphosphonate eligibility
zoledronic acid	is a	bisphosphonate
alendronate	is a	bisphosphonate
risedronate	is a	bisphosphonate
denosumab	is a	monoclonal antibody
monoclonal antibody	targets	RANKL
osteoporosis	screened for	secondary causes
secondary osteoporosis	includes	thyroid disease
thyroid disease	contributes to	osteoporosis
osteoporosis	worsened by	malnutrition
osteoporosis	improved by	nutrition optimization
humoral factors	regulate	bone remodeling
bone remodeling	involves	osteoclasts
osteoclasts	resorb	bone
osteoporosis	worsened by	chronic kidney disease
rheumatoid arthritis	predisposes to	osteoporosis
thyroid disease	predisposes to	osteoporosis
hypovitaminosis D	predisposes to	osteoporosis
calcium intake	reduces	fracture risk
vitamin D deficiency	increases risk of	osteoporosis
bone density	decreases with	age
senile osteoporosis	is a	variant of osteoporosis
bone density testing	notifies	osteoporosis progression
therapy adherence	influences	fracture risk reduction
fracture risk reduction	achieved by	osteoporosis therapies
pain	associated with	vertebral fractures
mobility	declines with	vertebral fractures
quality of life	declines with	fractures
healthcare cost	increases with	osteoporosis-related fractures
falls	trigger	fractures
secondary osteoporosis	caused by	malabsorption
parathyroid hormone therapy	used for	osteoporosis management
teriparatide	is a	PTH analog
sarcopenia	coexists with	osteoporosis
osteoporosis	associated with	frailty
calcium supplementation	reduces	fracture risk
vitamin D sufficiency	improves	bone health
exercise therapy	reduces	fracture risk
renal function impairment	modifies	osteoporosis management
